Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Neonatal fc receptor blockers
11 evidence topics · 11 sources
Mechanism, onset, and comparative effect of FcRn blockers: Nordic guidance
“Monoclonal antibodies directed at the FcRn receptor's binding site for IgG block recycling and lead to a 60%–70% reduction in circulating IgG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment can be tailored according to the disease state; new treatment cycles can be administered with signs of symptom worsening or according to a fixed schedule.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The number of treatment responders and the magnitude of the treatment response for FcRn blockers and complement inhibitors seem to be similar. No prospective and controlled head‐to‐head studies have been undertaken.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efgartigimod intravenous: FDA-labeled indication, dosing, and pivotal trials
Efgartigimod alfa and hyaluronidase subcutaneous: FDA-labeled indication and dosing
Rozanolixizumab: FDA-labeled indication, dosing, and pivotal trial
Nipocalimab: FDA-labeled indication, dosing, and pivotal trial
Efgartigimod intravenous: ADAPT phase 3 trial, AChR antibody-positive modified intention-to-treat population, first treatment cycle
“The primary endpoint was proportion of acetylcholine receptor antibody-positive patients who were MG-ADL responders (≥2-point MG-ADL improvement sustained for ≥4 weeks) in the first treatment cycle.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between Sept 5, 2018, and Nov 26, 2019, 167 patients (84 in the efgartigimod group and 83 in the placebo group) were enrolled, randomly assigned, and treated. 129 (77%) were acetylcholine receptor antibody-positive. Of these patients, more of those in the efgartigimod group were MG-ADL responders (44 [68%] of 65) in cycle 1 than in the placebo group (19 [30%] of 64), with an odds ratio of 4·95 (95% CI 2·21-11·53, p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Four (5%) efgartigimod-treated patients and seven (8%) patients in the placebo group had a serious adverse event.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Efgartigimod alfa and hyaluronidase subcutaneous: ADAPT-SC noninferiority trial, total IgG reduction at week 4
“The ADAPT-SC primary endpoint was met. The LSM estimate of percentage change from baseline in total IgG level at week 4 was −66.4% for the efgartigimod PH20 SC arm vs −62.2% for the efgartigimod IV arm (Table 2), giving a LSM difference of −4.2% (95% CI, −7.73 to −0.66).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of AChR-Ab+ participants in the efgartigimod PH20 SC and efgartigimod IV arms demonstrated similar percentages of MG-ADL responders (efgartigimod PH20 SC: 71.1%; efgartigimod IV: 71.7%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rozanolixizumab: MycarinG phase 3 trial, intention-to-treat population, day 43
“Between June 3, 2019, and June 30, 2021, 300 patients were assessed for eligibility, of whom 200 were enrolled. 66 (33%) were randomly assigned to rozanolixizumab 7 mg/kg, 67 (34%) to rozanolixizumab 10 mg/kg, and 67 (34%) to placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Reductions in MG-ADL score from baseline to day 43 were greater in the rozanolixizumab 7 mg/kg group (least-squares mean change -3·37 [SE 0·49]) and in the rozanolixizumab 10 mg/kg group (-3·40 [0·49]) than with placebo (-0·78 [0·49]; for 7 mg/kg, least-squares mean difference -2·59 [95% CI -4·09 to -1·25], p<0·0001; for 10 mg/kg, -2·62 [-3·99 to -1·16], p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent TEAEs were headache (29 [45%] patients in the rozanolixizumab 7 mg/kg group, 26 [38%] in the rozanolixizumab 10 mg/kg group, and 13 [19%] in the placebo group), diarrhoea (16 [25%], 11 [16%], and nine [13%]), and pyrexia (eight [13%], 14 [20%], and one [1%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Nipocalimab: Vivacity-MG3 phase 3 trial, antibody-positive intention-to-treat population, weeks 22 to 24
“Between July 15, 2021, and Nov 17, 2023, 199 patients were enrolled, and 196 patients received study drug (98 in the nipocalimab group and 98 in the placebo group); of these, 153 (77 in the nipocalimab group and 76 in the placebo group) were antibody-positive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The least-squares mean change in MG-ADL score from baseline to weeks 22, 23, and 24 was -4·70 (SE 0·329) in the nipocalimab group versus -3·25 (0·335) in the placebo group (difference -1·45 [95% CI -2·38 to -0·52]; p=0·0024).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Serious adverse events were reported for nine (9%) of 98 patients in the nipocalimab group and 14 (14%) of 98 patients in the placebo group, three of which had a fatal outcome (nipocalimab: myasthenic crisis; placebo: cardiac arrest and myocardial infarction).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FcRn inhibitor initiation, cycle timing, and IgG monitoring: German-Austrian expert recommendations
“Recommendation (strong consensus): Add‐on therapy with FcRn‐I should be considered for patients with (highly) active gMG (including therapy‐refractory disease) who are positive for AChR‐ and MuSK‐autoantibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation (strong consensus): Timing of a new FcRn‐I cycle should be individualised.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation (strong consensus): FcRn‐I therapy should be accompanied by monitoring of infections and IgG levels, particularly before initiation and, if needed, at the beginning and end of individual treatment cycles depending on the values obtained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote